Tag Cloud

What is a tag cloud?

Current tags: Clear current tags
View full tag cloud
Advertisement
Q

Is Campral ok to be used in a chronic alcoholic with abnormal LFTs (eg ALT of 350)?

Associated tags: acamprosate, alcohol misuse, ALT, cautions, contraindications, Gastroenterology, LFTs, Mental health

Question DetailsView Comments (0)
A

ANSWER

provided by Trip / NLH
Search
Moderate
Appraisal
Moderate
Confidence
Poor

Answer Rating key

search strong
appraisal weak
confidence moderate

Question answered:04/02/08 Warning! this question is over two years old.

We found no information concerning the suitability of prescribing acamprosate to a patient with abnormal liver function tests, namely alanine aminotransferase, and thus would advise contact a local specialist for advice or the manufacturers of this medication (see below).

 

The CKS guideline on problem drinking lists the following contraindications to prescribing acamprosate:

 

• “Acamprosate should not be used in the following circumstances [ABPI Medicines Compendium, 2003]:
o The person is a pregnant or breastfeeding woman.
o There is severe renal insufficiency (serum creatinine < 120 micromoles/L).
o There is severe hepatic failure (Childs-Pugh classification C).”
[1]

 

The same information is given in the SPC on Campral EC (acamprosate calcium). [2]

 

GPNotebook offers the following information on the Childs-Pugh classification scheme:

 

The Child- Pugh classification is a means of assessing the severity of liver cirrhosis.
Score 1 2 3
bilirubin (micromol/l) <34 34-50 >50
albumin (g/l) >35 28-35 <28
PT (s prolonged) <4 4-6 >6
encephalopathy none mild marked
ascites none mild marked
If there is primary biliary cirrhosis or sclerosing cholangitis then bilirubin is classified as <68=1; 68-170=2; >170=3.
The individual scores are summed and then grouped as:
• <7 = A
• 7-9 = B
• >9 = C

A C classification forecasts a survival of less than 12 months.” [3]

 

As mentioned above, we found no guidelines or studies discussing ALT levels in relation to prescribing acamprosate and thus would suggest contacting the pharmaceutical company for further assistance:

 

Merck Serono
Medical Information direct line: +44 (0)208 818 7373
Medical Information e-mail: medinfo.uk@merckserono.net

 

References
1. CKS. Alcohol – problem drinking. May 2007. (http://www.cks.library.nhs.uk/alcohol_problem_drinking/)
2. SPC for Campral EC. November 2007. (http://emc.medicines.org.uk/emc/industry/default.asp?page=displaydoc.asp&documentid=1042_)
3. GPNotebook. Child’s classification (liver cirrhosis). (http://www.gpnotebook.co.uk/simplepage.cfm?ID=201719830)


DISCLAIMER: TRIPanswers is a collection of clinical questions and answers.  Each provider will have their own methodology in answering questions and these are likely not to be as rigorous as systematic review.  If you have any doubt as to the implications of this contact the Q&A Service Provider for further information. This document is presented for information purposes only. This document cannot and should not be used as a basis of diagnosis or choice of treatment, and is in no way intended to replace professional medical care or attention by a qualified practitioner. TRIPanswers and TRIP Database Ltd are not responsible or liable for, directly or indirectly, ANY form of damage whatsoever resulting from the use/misuse of information contained in or implied by this document.  Also, ensure you have read the terms and conditions for using the site.

Need to search for more evidence?

Help us improve this answer

Leave comments or suggestions below

Disclaimer:

TRIP will review each comment and will only publish those we feel will enhance a particular answer.  As a result of the review process there will be a delay between submission and publication of accepted comments.